作者: Linghong Shen , Xiaoxiao Yang , Ben He , Xingbiao Qiu , Hongyu Shi
DOI: 10.1097/MD.0000000000025551
关键词:
摘要: Background The aim of the study was to evaluate efficacy nicorandil and alprostadil on myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI). Methods In this prospective, single-blinded, randomized controlled study, 90 consecutive scheduled for PCI de novo lesions were assigned nicorandil, alprostadil, nitroglycerin groups a 1:1:1 ratio. Drugs administered intracoronary via targeted perfusion microcatheter. primary endpoint thrombolysis infarction (TIMI) frame count (TMPFC). Additionally, corrected TIMI (cTFC), grade (TMPG), incidence periprocedural injury (PMI) assessed. Results Both significantly effective reducing TMPFC (114.6 ± 33.7 vs 93.4 30.9, P = .016; 114.3 34.3 94.7 33.3, .029, respectively). Similar findings observed improvement cTFC (20.3 10.5 13.5 5.0, .003; 20.2 7.4 15.2 5.2, .003, respectively) percentage TMPG 3 (100% 82.8%, .052; 83.3% 96.7%, .196, respectively); whereas, produced limited effect (114.4 30.9 112.1 31.9, .739), (19.4 7.2 19.3 7.2, .936), (86.7% 86.7%, 1.000). No significant difference found PMI (16.7% 16.0% 27.6%, .537), though it comparatively lower groups. Furthermore, administration had mild blood pressure heart rate. Conclusions microcatheter more improving than nitroglycerin.